Treatment Strategies for the Opioid-Dependent Patient
Purpose of Review
This review is intended to help the headache physician think through and plan for management issues concerning the use of opioids. We ask the headache physician to consider if there are instances where prescribing or continuing prescriptions of opiates is plausible, and if so, how can the physician proceed as safely as possible. Our goal is to start a conversation regarding the inevitable encounter with a patient on opiates or requesting opiates.
The use of opiates in our society has reached a crisis in staggering death and addiction rates. Recent guideline published by the CDC can assist us in developing an algorithmic approach towards opiate use. Recent advances in addiction medicine can also assist us in protecting our patients.
Every headache physician will undoubtedly encounter patients on opiates. There still are appropriate reasons to treat patients with opiates. Every headache physician may need to prescribe opiates and they may be indicated. It is important to learn the correct way to approach, manage, and treat patients on opiates.
KeywordsAddiction Opiate abuse Prescribing opiates Opioid management
We would like to thank Anna Lembke and Howard Kornfeld for their assistance with this manuscript.
Compliance with Ethical Standards
Conflict of Interest
Shweta Teckchandani declares that he has no conflict of interest. Meredith Barad reports participation in clinical trials supported by ATI, Alder, Lilly, Capnia, TEVA, and Allergan.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Warner M, Trinidad JP, Bastian BA, Minino AM, Hedegaard H. Drugs most frequently involved in drug overdose deaths: United States, 2010–2014. Natl Vital Stat Rep. 2016;65(10):1–15.Google Scholar
- 4.• Katz J. Drug deaths in America are rising faster than ever. New York Times. 2017 June 5, 2017. The New York Times has partnered with the CDC to predict drug overdose deaths for 2016.Google Scholar
- 5.Lopez G. In one year, drug overdoses killed more Americans than the entire Vietnam War did 2015 was the worst year for drug overdose deaths in US history. Then 2016 came along. Vox News. 2017; https://www.vox.com/policy-and-politics/2017/6/6/15743986/opioid-epidemic-overdose-deaths-2016;
- 7.Perez-Pena R. Ohio sues drug makers, Saying They Aided Opioid Epidemic New York Times. 2017 31, 2017.Google Scholar
- 11.Choong CK, Ford JH, Nyhuis AW, Joshi SG, Robinson RL, Aurora SK, et al. Clinical characteristics and treatment patterns among patients diagnosed with cluster headache in U.S. healthcare claims data. Headache. 2017; https://doi.org/10.1111/head.13127.
- 13.•• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016. 65(RR-1):1–49. 10.15585/mmwr.rr6501e1. Another version of the above paper published by the CDC.
- 17.Bjornsdottir SV, Triebel J, Arnljotsdottir M, Tomasson G, Valdimarsdottir UA. Long-lasting improvements in health-related quality of life among women with chronic pain, following multidisciplinary rehabilitation. Disabil Rehabil. 2017:1–9. https://doi.org/10.1080/09638288.2017.1312565.
- 18.Hadi MA, Alldred DP, Briggs M, Marczewski K, Closs SJ. ‘Treated as a number, not treated as a person’: a qualitative exploration of the perceived barriers to effective pain management of patients with chronic pain. BMJ Open. 2017;7(6):e016454. https://doi.org/10.1136/bmjopen-2017-016454.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. Natl Health Stat Report. 2015(79):1–16.Google Scholar
- 21.• Cook KF, Jensen SE, Schalet BD, Beaumont JL, Amtmann D, Czajkowski S, et al. PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. J Clin Epidemiol. 2016;73:89–102. https://doi.org/10.1016/j.jclinepi.2015.08.038. An examination of the validity of the NIH’s Patient Reported Outcome Measurement Information Systems across different populations.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–86. https://doi.org/10.7326/M14-2559.CrossRefPubMedGoogle Scholar
- 28.Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557–64. https://doi.org/10.1097/AJP.0000000000000021.PubMedPubMedCentralGoogle Scholar
- 30.Brown EG, Serrano D, Kirchmeyer K. Guideline for prescribing controlled substances for pain. In: California MBo, editor. Calfornia. 2014; https://www.mbc.ca.gov/licensees/prescribing/pain_guidelines.pdf.
- 31.Brennen MJ, Fudin J, Perkins RJ. Opioid calculator. Practical Pain Management. 2017. Accessed 29 June 2017.Google Scholar
- 32.Kaplovitch E, Gomes T, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLoS One. 2015;10(8):e0134550. https://doi.org/10.1371/journal.pone.0134550.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Emery MA, Bates ML, Wellman PJ, Eitan S. Differential effects of oxycodone, hydrocodone, and morphine on activation levels of signaling molecules. Pain Med. 2015; https://doi.org/10.1111/pme.12918.
- 35.HHS. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. In: Quality CfBHSa, editor. HHS Publication No. SMA 16–4984, NSDUH Series H-512016. https://www.samhsa.gov/data/
- 38.• Yarborough BJ, Stumbo SP, Janoff SL, Yarborough MT, McCarty D, Chilcoat HD, et al. Understanding opioid overdose characteristics involving prescription and illicit opioids: a mixed methods analysis. Drug Alcohol Depend. 2016;167:49–56. https://doi.org/10.1016/j.drugalcdep.2016.07.024. This study looks more deeply at the phenotype of opiate abusers, by investigating the context of their abuse and their life circumstances.CrossRefPubMedGoogle Scholar
- 42.• Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone. J Subst Abus Treat. 2017; https://doi.org/10.1016/j.jsat.2017.04.016. This medication may be a breakthrough in the treatment of opioid abuse, stay tuned.
- 47.• Kornfeld H. Buprenorphine: everything you need to know. California Healthcare Foundation. 2016:1–11. A very practical paper for how to prescribe and use buprenorphine.Google Scholar
- 49.• Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174(5):459–67. https://doi.org/10.1176/appi.ajp.2016.16050548. Another study examining the potential of injectable naltrexone.CrossRefPubMedGoogle Scholar
- 50.Mannelli P, Wu LT, Peindl KS, Swartz MS, Woody GE. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend. 2014;138:83–8. https://doi.org/10.1016/j.drugalcdep.2014.02.002.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Lee SY, Chen SL, Chang YH, Chu CH, Chen SH, Chen PS, et al. A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment. Int J Neuropsychopharmacol. 2015;18(7):pyv008. https://doi.org/10.1093/ijnp/pyv008.CrossRefPubMedPubMedCentralGoogle Scholar